Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Canghan paste navel tablet is a traditional Chinese medicine (TCM) hospital preparation developed by Shuguang Hospital, which is affiliated with the Shanghai University of Traditional Chinese Medicine. It is specifically formulated for the treatment of infertility associated with "Cold-Dampness Stagnation" (often referred to as "Uterine Cold" or Gonghan). The medication is administered topically to the Shenque point (the navel), a practice known as umbilical therapy (脐疗), which facilitates the absorption of herbal active ingredients to warm the uterus, dispel cold, and improve local blood circulation. Clinical studies have suggested that the preparation may enhance endometrial receptivity and regulate the reproductive environment, thereby improving pregnancy outcomes in women with cold-related fertility issues. As a registered hospital preparation in Shanghai, its use is primarily concentrated within the Shuguang Hospital healthcare system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Canghan paste navel tablet.